



Stabilis



Melatonin



Stability of pharmaceutical preparations

		1000 mg	Stevia powder 250 mg Ethanol 15 ml Fruit aroma 2 ml Glycerin >> 100 ml	24-26°C		90		2872
		120 mg ® = ?	Inorpha® >> 60 mL	25°C		126		761
		60 mg ® = ?	SyrSpend SF® >> 20 ml	25°C		90		4198
		1000 mg	Stevia powder 250 mg Ethanol 15 ml Fruit aroma 2 ml Glycerin >> 100 ml	3-5°C		90		2872
		120 mg ® = ?	Inorpha® >> 60 mL	4°C		126		761
		60 mg ® = ?	SyrSpend SF® >> 20 ml	4°C		90		4198
		60 mg ® = ? (CVS Pharmacy)	OraPlus® / OraSweet® (1:1) >> 60 ml	23-25°C		90		3187
		60 mg ® = ? (CVS Pharmacy)	OraPlus® / OraSweet SF® (1:1) >> 60 ml	23-25°C		90		3187
		60 mg ® = ?	Oral Mix SF® >> 30 ml	23-27°C		90		3861
		60 mg ® = ?	Oral Mix SF® >> 30 ml	3-5°C		90		3861
		2 mg ® = ?	Oral Mix SF® >> 1 ml	23-27°C		90		3861
		2 mg ® = ?	Oral Mix SF® >> 1 ml	3-5°C		90		3861



Factors which affect stability




References

	Type	Publication
761	Journal	Zerbit J, Bordenave J, Benoit G. Physicochemical and microbiological stability studies of a melatonin oral suspension in a commercially available vehicle for paediatric use. EJHP 2015 ;22:89-93
2872	Journal	Haywood A, Burrell A, van Breda K, Testa C, Norris R. Stability of Melatonin in an Extemporaneously Compounded Sublingual Solution and Hard Gelatin Capsule Int J Pharm Compound 2009 ; 13, 2: 170-174.
3187	Journal	Johnson CE, Cober MP, Thome T, Rouse E. Stability of an extemporaneous alcohol-free melatonin suspension. Am J Health-Syst Pharm 2011 ; 68:420-423.
3861	Journal	Friciu M , Savji T , Zarea S, Leclair G. Evaluation of stability of melatonin in extemporaneously compounded oral suspensions. J Pharm Pract and Res 2016 ; 46: 28-33.
4198	Journal	Uriel M, Gomez-Rincon C, Marro D. Stability of regularly prescribed oral liquids formulated with SyrSpend® SF. Pharmazie 2018 73;196-201

Stabilis



Melatonin



Stability of pharmaceutical preparations

		3 mg	Food coloring 100 mg Methocel E4M® 100 mg Lactose 220 mg	24-26°C		90		2872
		3 mg	Food coloring 100 mg Methocel E4M® 100 mg Lactose 220 mg	39-41°C		90		2872
		0,5 mg @ = Inresa	Microcrystalline cellulose 77 mg	23-27°C		547		4079
		2 mg @ = Inresa	Microcrystalline cellulose 75,5 mg	23-27°C		547		4079
		6 mg @ = Inresa	Microcrystalline cellulose 71,5 mg	23-27°C		547		4079



Factors which affect stability































References

Type	Publication
2872 Journal	Haywood A, Burrell A, van Breda K, Testa C, Norris R. Stability of Melatonin in an Extemporaneously Compounded Sublingual Solution and Hard Gelatin Capsule Int J Pharm Compound 2009 ; 13, 2: 170-174.

4079	Journal	Filali S, Bergamelli C, Tall M.L, Salmon D, Laleye D, Dhelens C, Diouf E, Pivot C, Pirot F. Formulation, stability testing, and analytical characterization of melatonin-based preparation for clinical trial. J Pharm Anal 2017 ; 7, 4: 237-243.
------	---------	---



Dictionary

 Hormone	 Oral solution
 Stability of pharmaceutical preparations	 Container
 Origine	 Excipient
 Temperature	 Storage
 Length of time	 Biosimilar
 Conflicting data	 References
 Glass	 Powder
 Protect from light	 Day
 Not specified	 Plastic bottle
 Tablets	 Syringe
 Factors which affect stability	 Light
 Induces	 Degradation
 References	 Capsule
 Not specified	 Dictionary